The Use Of MicroRNA As Novel Therapeutic Targets For Reducing Retinal Inflammation And Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$349,076.00
Summary
Age-Related Macular Degeneration (AMD) is the most common cause of blindness in Australia. We aim to investigate a new class of potential therapeutics, microRNA which are involved in the regulation of many biological processes, including inflammation. A greater understanding of these miRNA will enable discovery of novel therapeutic targets for inflammatory diseases like AMD, and will have further reaching applications in other inflammatory disease such as Alzheimer’s and Parkinson’s.
The Treatment Of BOoking Gestational Diabetes Mellitus Study: The TOBOGM Study
Funder
National Health and Medical Research Council
Funding Amount
$2,197,280.00
Summary
Gestational diabetes mellitus (GDM) related pregnancy complications are reduced with treatment from 24-28 weeks pregnant. Many women are diagnosed/treated earlier without evidence of benefit and possible risk of harm. In TOBOGM women under 20 weeks pregnant with mildly raised blood glucose will be allocated by chance to either immediate treatment, or awaiting a repeat diabetes test at 24-28 weeks pregnant to decide treatment. Harmful and beneficial effects on mother and baby will be compared.
The Effects Of Oxytocin Nasal Spray On Mechanisms Of Social-communication In Young People With Autism
Funder
National Health and Medical Research Council
Funding Amount
$191,400.00
Summary
Autism is charcterised by deficits in social behaviour and communication, and is a cause of major lifelong disability. A novel intervention, Oxytocin, enhances social communication in non-clinical populations. This project will determine whether OT improves social communication deficits characteristic of autism. This project is a critical first step towards treating a core deficit of autism.